Condition (MeSH)
Leishmaniasis, Mucocutaneous
ClinicalTrials.gov lists 21 trials for Leishmaniasis, Mucocutaneous or a narrower condition beneath it. Knight Therapeutics (USA) Inc has the most among industry and government lead sponsors, with 3.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
21 of the 21 trials are tagged with Leishmaniasis, Mucocutaneous itself; the rest are tagged with a narrower condition beneath it.
When did Leishmaniasis, Mucocutaneous trials start? (15)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 2/3
- Phase 3
- Not applicable
- Observational
Top of scale: 3
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 1 |
| 2025 | 2 |
| 2023 | 1 |
| 2022 | 1 |
| 2021 | 2 |
| 2020 | 1 |
| 2019 | 3 |
| 2017 | 1 |
| 2015 | 2 |
| 2014 | 1 |
Showing 10 of 15 earlier years.
No forecast is made for this condition: it averages 1.0 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 2 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Leishmaniasis, Mucocutaneous trials in? (8)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 2 |
| Phase 1/2 | 2 |
| Phase 2 | 5 |
| Phase 2/3 | 5 |
| Phase 3 | 1 |
| Not applicable | 1 |
| Observational | 4 |
| Expanded access | 1 |
How many Leishmaniasis, Mucocutaneous trials are recruiting? (5)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 1 |
| Recruiting | 3 |
| Completed | 11 |
| No longer available | 1 |
| Unknown status | 5 |
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Leishmaniasis, Mucocutaneous trials? (3)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Knight Therapeutics (USA) Inc | 3 |
| Infan Industria Quimica Farmaceutica Nacional | 1 |
| National Institute of Allergy and Infectious Diseases (NIAID) | 1 |
Which drugs are being tested for Leishmaniasis, Mucocutaneous? (3)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Miltefosine | 7 |
| Meglumine Antimoniate | 3 |
| Paromomycin | 2 |
Interventions as named in the registry (12)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| liposomal Amphotericine B | 3 |
| 18-Methoxycoronaridine | 1 |
| Group 2: Pentavalent Antimony | 1 |
| Immucillin DI4G | 1 |
| Group 1: Miltefosine | 1 |
Showing 5 of 12 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which publications cover Leishmaniasis, Mucocutaneous? (19)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| The cure rate after different treatments for mucosal leishmaniasis in the Americas: A systematic review. | PLoS neglected tropical diseases | 2022 | Yes |
| Efficacy and safety of pentamidine isethionate for tegumentary and visceral human leishmaniasis: a systematic review. | Journal of travel medicine | 2021 | Yes |
| Mucosal leishmaniasis: A Retrospective Study of 327 Cases from an Endemic Area of <i>Leishmania</i> (<i>Viannia</i>) <i>braziliensis</i>. | The American journal of tropical medicine and hygiene | 2017 | Yes |
| Therapeutic options for old world cutaneous leishmaniasis and new world cutaneous and mucocutaneous leishmaniasis. | Drugs | 2013 | Yes |
| Randomized controlled clinical trial to access efficacy and safety of miltefosine in the treatment of cutaneous leishmaniasis Caused by Leishmania (Viannia) guyanensis in Manaus, Brazil. | The American journal of tropical medicine and hygiene | 2011 | Yes |
Showing 5 of 19 publications.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: serious adverse events in this condition's trials, prevalence, rare-disease identity, and sub-conditions in mesh.